

Prescription Enrollment Form

NerivioNow

Nerivio®

Questions?
Call the Nerivio Support
Team: (937) 637-4846

Prescribers: Please complete this form in its entirety & attach Patient Face Sheet,
then fax to: (888) 214-0258

PATIENT INFORMATION

Patient Name: _____ DOB: _____ Sex: _____
Address: _____
City: _____ State: _____ Zip Code: _____
Cell Number: _____ E-mail: _____

INSURANCE INFORMATION

Insurance Company: _____ Plan/Group Name: _____
Member ID: _____ Group Number: _____
Policyholder's Name: _____ Policyholder's DOB: _____

PRESCRIBER INFORMATION

Prescriber Name: _____ Clinic: _____
Clinic Address: _____ NPI: _____
City: _____ State: _____ Zip Code: _____
Office Contact: _____ Email: _____
Primary Phone: _____ Fax Number: _____

PRESCRIPTION INFORMATION

Check the appropriate ICD-10 code (required):

- Checkboxes for ICD-10 codes: G43.001, G43.009, G43.011, G43.019, G43.101, G43.109, G43.111, G43.119, G43.701, G43.709, G43.711, G43.719, Other: G43. _____

Additional Clinical Information (Please check all that apply):

- Patients at risk of drug-drug interaction with other medications.
Pregnant women, women who are trying to conceive, or are breast-feeding.

If applicable, check all acute and/or preventive treatments that have been tried.

- Triptans, NSAIDS/oral analgesics, Gepants, Ditans, Ergots, Antiepileptics, Beta Blockers, Monoclonal Antibodies, Botox, Antidepressants, Other: _____

Directions & Nerivio Quantity (required):

Set a strong, yet comfortable intensity level for each 45 min treatment.

- Acute: 45 min treatment at onset of migraine. 1 Initial Fill + 12 Refill Units
Prevention: 45 min treatment every other day, or as directed.
Dual Use: 45 min treatment every other day for prevention and/or at onset of migraine.
30 Day Supply (1 Initial fill) + 12 Refill Units
90 Day Supply (3 Initial fills) + 12 Refill Units
Additional Refill Qty: _____

Prescriber Signature: _____ Date: _____

Nerivio prescriptions can be submitted to RISRx Pharmacy via your EMR or via FAX

PRESCRIBING NERIVIO VIA YOUR ELECTRONIC MEDICAL RECORD (EMR) SYSTEM

1. Select "Retail" Pharmacy from your EMR search library by using the following criteria;

eRx Pharmacy Name: Pacific LTC Pharmacy			
NCPDP / NABP#	5664417	NPI #	1871002485
Phone (not for Rx or patient support): (949) 524-3566			
Address:	361 Hospital Rd. Suite 425 Newport Beach, CA 92663		

2. In the notes section **MUST** include:

- a) "Nerivio"
- b) Number of Refills
- c) Diagnosis Code
- d) One of these instructions for use:
 - Acute: 45 minute treatment at onset of migraine
 - Prevention: 45 minute treatment every other day, or as directed
 - Dual Use: 45 minute treatment every other day for prevention and/or at onset of migraine

3. Attach patient demographic sheet to include:

- Any additional clinical criteria
- Chart notes from recent visits
- Medical Insurance information
- o If unable to locate the pharmacy/distributor in your search library, contact your EMR administrator or EMR software vendor and ask to have this pharmacy/distributor added to your system
- o **To reach the pharmacy directly regarding a specific prescription, please call 1 888-214-6693**
- o If you require additional assistance, please call Nerivio Cares at (937) 637-4846 or email at support@nerivio.com

PRESCRIBING NERIVIO VIA FAX

1. FAX the following to 1 888-214-0258

- The completed Nerivio Enrollment Form
- Patient demographic face sheet
- Chart notes from recent visits
- Medical insurance information
- o If you require additional assistance, or need a copy of the Nerivio Prescription Enrollment form, please call Nerivio Cares at (937) 637-4846 or email at support@nerivio.com

Nerivio[®]

by theranica

Complete Migraine Care

One Device for Effective Migraine Prevention and Treatment

Nerivio is a wearable migraine therapy that is safe and effective for preventing and treating migraine in patients ages 8 years and up.

Preventing Migraine¹

4
LESS
Monthly
Migraine
Days




Over half
of patients
had a

≥50%
reduction

in moderate
to severe
headache days.

Acute Treatment of Migraine²

Adults at 2-hours Post Treatment



Clinical trials demonstrate that Nerivio provides consistent relief of pain and associated migraine symptoms, as well as significant reduction in monthly migraine days

Effective • Drug Free • Discreet • Wearable

Nerivio is safe and well tolerated with no systemic side effects or concern for medication overuse.

Nerivio
by **theranica**


57% of Adult Chronic patients achieved relief 2-hours post treatment with Nerivio.^{3,4}

72% of children⁵ and adolescents⁶ achieved pain relief 2-hours post treatment with Nerivio.

Pivotal Acute RCT* in Adult Episodic Patients²

(* Randomized Controlled Trial)

Prospective, randomized, double-blind, placebo controlled, multi-center study (n=252)




After only one month, patients using Nerivio every other day showed a significant reduction in the number of migraine days per month.¹

Pivotal Prevention RTC*

(* Randomized Controlled Trial)

Prospective, randomized, double-blind, placebo controlled, multi-center study (n=248)



Significant reduction of MMD was reported in patients whether or not they were taking other preventive treatment in addition to Nerivio vs. placebo (p ≤ 0.03).

Of the 128 Nerivio patients studied, zero patients reported device related adverse events in the pivotal prevention trial.¹

Scan here for clinical study info



- Tepper SJ, et al. Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial. *Headache*. 2023 Mar;63(3):377-389. doi: 10.1111/head.14469.
- Yarnitsky D, et al. Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. *Headache*. 2019 Sep;59(8):1240-1252. doi: 10.1111/head.13551.
- Nierenburg H, et al. Remote Electrical Neuromodulation for the Acute Treatment of Migraine in Patients with Chronic Migraine: An Open-Label Pilot Study. *Pain Ther*. 2020 Dec;9(2):531-543. doi: 10.1007/s40122-020-00185-1.
- Grosberg B, et al. Safety and efficacy of remote electrical neuromodulation for the acute treatment of chronic migraine: an open-label study. *Pain Rep*. 2021 Oct 14;6(4):e966. doi: 10.1097/PR9.0000000000000966.
- Werner K, et al. Acute treatment of migraine in children aged 6–11: Real-world analysis of remote electrical neuromodulation (REN). *Annals of the Child Neurology Society*. 2024 June;2(2): 135-145. doi.org/10.1002/cns3.20073.
- Hershey AD, et al. Remote electrical neuromodulation for acute treatment of migraine in adolescents. *Headache*. 2021 Feb;61(2):310-317. doi.org/10.1111/head.14042.

Scan here for important safety info

